The aggregate proceeds of the company’s IPO and private placement were $24 million. The proceeds will be used to finance Check-Cap’s clinical program, product development and corporate purposes.
The company’s shares began trading on the NASDAQ Capital Market on Feb. 19 under the ticker symbol “CHEKI.”
The company’s product is a preparation-free, ingestible imaging capsule designed for colorectal cancer screening.
More articles on gastroenterology:
AGA to hold workshop on effective scope cleaning
RD Biomed to launch study in China to examine reflux disease diagnostic device
Dr. Amar Naik joins Loyola University Health System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
